TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Execution time for assignments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New diabetes incidence
Endpoint domain: Adverse events/effects
Primary endpoint: end-of-treatment complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to late AMD in the non-study eye
Endpoint domain: Mortality/survival
Primary endpoint: Rate of BCVA decline in the study eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: umbilical artery lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: global cerebral volume reductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum alanine aminotransferase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NAFLD activity scores (NAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete PV isolation (PVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rates of response stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS-pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC total scores reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wet weight absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Growth (weight and knemometry)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of malaria prevention strategies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of services received
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Health implications for mothers and babies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spatial working memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Declarative memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Intensity of exercise sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events during exercise sessions
Endpoint domain: Adverse events/effects
Primary endpoint: Postintervention exercise time at constant work rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak workload at incremental cardiopulmonary exercise test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall learning efficiency
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Self-awareness regarding post-test results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in urinary protein:creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: total duration of exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functioning scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Increased GLP-1 and PYY secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Decreased ad libitum energy intake (EI) at lunch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VAS-rated fullness and satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incidence of medical complications
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of biomechanical complications
Endpoint domain: Adverse events/effects
Primary endpoint: transfusion requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: time spent viewing webpages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CTX-II levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: medical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of seizures recurring
Endpoint domain: Mortality/survival
Primary endpoint: pain intensity during active and passive shoulder movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain-free passive shoulder abduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: snore index (snores > 36 dB/h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total snore index (total power of snore/h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of HbA(1c) target (< 7.0%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median score of participants
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean area under the plasma concentration-time curve (AUC(0-infinity))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent elimination half-life (T1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free Survival (PFS) by RECIST v1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate by modified RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in grade of hoarseness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in roughness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in asthenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough threshold response to capsaicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Risk of psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Survey of Academic Self‐Regulation (SASR) scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Performance Assessment Tool (PAT) 17‐critical steps scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median residual refractive cylinder value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median postoperative pain scores
Endpoint domain: Adverse events/effects
Primary endpoint: Successful femoral nerve block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activities of daily living participation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: daily mean bilirubin decrement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: apolipoprotein E
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Heart Rate (HR) and Skin Conductance Level (SCL) indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroconversion rates for JE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: VAS pain score 6 or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hours with VAS score 6 or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood estradiol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Primary hemostasis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percentage of time with intragastric pH > 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of hypersensitivity reaction to abacavir
Endpoint domain: Adverse events/effects
Primary endpoint: Control of symptoms of perennial allergic rhinitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intraindividual biological variability of LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative pressure spikes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Rise in IOP > or = 6 mmHg
Endpoint domain: Adverse events/effects
Primary endpoint: Time to target temperature (≤ 34 °C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Poor neurological outcome
Endpoint domain: Mortality/survival
Primary endpoint: Desensitization rate at 5 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Fasting fractional DNL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute lipogenesis area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Basal rates of glucose oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ABI postexercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stomatitis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stomatitis duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confidence scores for correct tube placement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of all clinical adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of clinical serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of fistula formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: combined endpoint of ischemic events, death, reinfarction, target lesion revascularization
Endpoint domain: Mortality/survival
Primary endpoint: RBC acetaldehyde levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma acetaldehyde levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sustained corticosteroid‐free clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained composite outcome of clinical remission, C‐reactive protein ≤0.5 mg/dL, and calprotectin ≤150 µg/g
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: OHRQoL improvement (OHIP-49 score)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: OHRQoL improvement (OHIP-EDENT score)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Memory/Attention/Decision Making
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of stroke and systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: Intestinal permeability (lactulose/mannitol ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum change in blood catechin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sacin values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in speeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1-change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Treatment Burden
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Withdrawal due to HAART-related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: reductions in mood symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weeks 9 through 12 continuous quit rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weeks 9 through 52 abstinence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: false positive recall rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of critical treatment steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete 50% and 75% of items
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in impulsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total physical activity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: future healthy function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency of circulating MDSCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of grade 3 or 4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Length of stay in the PICU
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Sexual health education program impact on sexual behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resumption of sexual life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: mean propofol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean times from termination of anesthetic to eye opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steward Recovery score of 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of nonvertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VE/VCO(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory muscle strength and endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Index of Pulmonary Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of respiratory complications
Endpoint domain: Adverse events/effects
Primary endpoint: blood cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Confidence in patient interactions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: hot flash reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recall rate at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention rate for G‐Bond and Optibond FL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of small enamel marginal defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ventricular rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Renoprotective effect of K+ supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Peripheral edema events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in functional disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of responders with at least 50% reduction in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OKS (Oxford Knee Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood product transfusion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedure-related bleeding complications
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of clinically relevant responders (≥30% NRS improvement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Back pain levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Örebro scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax post second dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent oral volume of distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to intraoperative analgesic rescue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First intake of analgesic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: central subfield thickening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual defect score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: objective estimate of ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: shortening of QS2c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: shortening of PEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Medication adherence as proportion of days covered (PDC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life improvement (Minnesota Living with Heart Failure Questionnaire scores)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: live-birth rates
Endpoint domain: Mortality/survival
Primary endpoint: Understanding of sterilization process
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: overall relationship satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Immunogenicity of PncDT11 vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: appetite before breakfast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of development of gastric and duodenal ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number of plaque covered teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: denture hygiene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engagement in mental health treatment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Retention in mental health treatment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Improvement in reproductive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: global subjective cosmetic outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: severity of telangiectasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: BRA value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mammography completion within 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: recovery trend in PD-Q scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SICI reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Defibrillation energy (E50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ventricular effective refractory period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ventricular fibrillation cycle length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Morning cortisol variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Synovial sac thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Knee pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency of Graves' disease complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thyrotoxicosis recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total body fat reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent leg fat reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pedaling time increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: forward movement of subspinale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symmetrical changes of the landmarks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3D changes of maxillary skeletal landmarks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of infusion reactions (IRs)
Endpoint domain: Adverse events/effects
Primary endpoint: leukocyte ROCK2 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily average exercise time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of IFG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes